Introduction
The COVID-19 pandemic highlighted the role of poor indoor air quality (IAQ) in furthering disease transmission and has led to calls to improve IAQ and indoor environmental quality (IEQ) to prepare for future pandemic preparedness. Reducing disease transmission indoors limits disease transmission and could provide time to develop effective countermeasures to a novel pathogen [
1]. Increased awareness of the role IAQ has on health and disease transmission has resulted in a series of policy actions and recommendations to promote healthy indoor air and limit the spread of respiratory pathogens indoors [
2]. The Biden-Harris Administration responded to the need for improved air quality by allocating
$350 billion to the Coronavirus State and Local Fiscal Recovery Funds (SLFRF) program, as well as an additional
$120 billion earmarked to improve air quality in schools. In tandem, the Centers for Disease Control and Prevention (CDC) developed recommendations that organizations, including employers and business owners, aim for 5 air-changes-per-hour (ACH) in their buildings to improve indoor air quality and prevent the spread of COVID-19 and other respiratory pathogens [
3]. However, funding alone does not implement effective responses to disease transmission indoors. To successfully and sustainably implement measures to clean the air of respiratory byproducts and disinfect it from respiratory pathogens, policy coupled with engineered solutions are necessary.
Engineered solutions may prevent the spread of pathogens that transmit through the air, reducing disease transmission. Behavioral interventions - such as mask-wearing, social distancing, limiting time indoors, or vaccination - continue to receive pushback from the public, despite continued evidence supporting their effectiveness [
4]. Engineering controls provide a proven, powerful, and unobtrusive means to increase public health. Engineered controls complement public health responses providing scalable and sustainable means to implement public health without needing to rely on individual compliance. Improving IAQ and reducing disease, engineering controls provide a continuous, resilient solution to create healthier indoor environments.
One engineering control proven effective to both clean indoor air and reduce the spread of respiratory pathogens is germicidal ultraviolet (GUV) energy, previously called ultraviolet germicidal irradiation. Producing a wavelength of 254 nm, GUV effectively kills pathogens and disinfects indoor environments [
5], and has been successfully deployed in the upper room in a series of high-risk environments, such as hospital operating rooms, to reduce disease transmission, with particular success at countering TB [
6]. Despite its effectiveness, GUV has not been broadly implemented in mass due the harm it can have on human tissues when they are over-exposed, causing sunburn (skin erythema) and external eye inflammation (photokeratitis and photoconjunctivitis) [
7]. GUV fixtures require expert installation and maintenance to ensure inadvertent over-exposure does not occur; they may face regulatory standards adding to the costs of installation; and is difficult to retrofit the fixtures into older buildings. GUV at 254nm is usually deployed in the upper parts of rooms or in unoccupied spaces of specific buildings such as hospitals. While these concerns have limited the adoption of GUV as an engineering control, there is renewed interest in using fixtures that enclose GUV 254nm, drawing air through them to inactivate pathogens, reducing the risks of inadvertent exposure.
A new technology, FAR-UV, has the potential to expand the use of UV irradiation as a tool to counter respiratory pathogens transmission indoors and enhance indoor air quality. FAR-UV is a germicidal ultraviolet energy without the drawbacks of 254 nm GUV. Producing light between 200-235 nm [
8], available evidence demonstrates how FAR-UV effectively kills respiratory pathogens with minimal or no nucleic acid or protein damage to human epithelial cells and eyes. [
8,
9,
10,
11,
12,
13,
14,
15,
16,
17]. Unlike GUV, FAR-UV energy fixtures do not require expert installation or maintenance, raising the possibility of mass adoption. FAR-UV is a potentially exciting new engineered solution to reduce indoor disease transmission, providing the benefits of GUV of improved IAQ and reduced disease transmission in more and novel spaces, at potentially lower costs and with less risk to human tissues.
Though initial studies of FAR-UV are promising, there are safety and efficacy questions that require additional research, particularly related to long-term exposure of human tissue to FAR-UV and the interactions of this higher-frequency energy with the indoor environment. To address these research gaps, with the support of Effective Giving, the OSLUV Project, and Blueprint Biosecurity, the Johns Hopkins Center for Health Security hosted a 1-day not-for-attribution meeting on February 27, 2024, in Washington, DC, convening 54 experts from academia, government, and industry to discuss current research about the effectiveness and use of FAR-UV; how FAR-UV compares to other technologies including GUV at 254nm; and any outstanding questions about safety efficacy, and feasibility for implementation. Experts presented on a range of topics, including, efficacy, the role of engineering controls, indoor chemistry considerations, energy efficiency, impacts on eyes, skin, and respiration, environmental effects, ozone and oxidation products, regulatory issues, and standards development. These plenaries were followed by moderated discussion. In this work, we explore the research areas discussed in the workshop, summarize the findings, and provide a commentary and recommendations for the implementation of FAR-UV and the regulatory frameworks surrounding this new technology.